• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

抗磷脂抗体与危重症 COVID-19 患者的血栓并发症有关吗？

Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?

机构信息

Laboratory of Hematology, Lariboisière Hospital, Paris University, Paris, France; INSERM UMRS 1140, Paris University, Paris, France.

Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Paris University, Paris, France; INSERM UMRS 1144, Paris University, Paris, France.

出版信息

Thromb Res. 2020 Nov;195:74-76. doi: 10.1016/j.thromres.2020.07.016. Epub 2020 Jul 8.

DOI:10.1016/j.thromres.2020.07.016
PMID:32663703
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7342042/
Abstract

• The prevalence of aPL antibodies is poorly documented in ICU COVID-19 patients. • LA based on dRVVT system was positive in 85% of critically ill COVID-19 patients. • LA was not associated with thrombotic complications. • The prevalence of elevated anticardiolipin IgG/M/anti-beta2-GPI IgG was of 12%.

摘要

• ICU 中 COVID-19 患者的 aPL 抗体流行情况记录不佳。

• 基于 dRVVT 系统的 LA 在 85%的危重症 COVID-19 患者中呈阳性。

• LA 与血栓并发症无关。

• 升高的抗心磷脂 IgG/M/抗β2-GPI IgG 的患病率为 12%。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bce0/7342042/653de56e6243/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bce0/7342042/653de56e6243/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bce0/7342042/653de56e6243/gr1_lrg.jpg

相似文献

1
Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?抗磷脂抗体与危重症 COVID-19 患者的血栓并发症有关吗？
Thromb Res. 2020 Nov;195:74-76. doi: 10.1016/j.thromres.2020.07.016. Epub 2020 Jul 8.
2
Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients.危重症 COVID-19 患者的天然抗凝剂、凝血因子和抗磷脂抗体谱。
J Thromb Thrombolysis. 2020 Oct;50(3):580-586. doi: 10.1007/s11239-020-02182-9.
3
Clinically significant anticardiolipin antibodies associated with COVID-19.与 COVID-19 相关的临床显著抗心磷脂抗体。
J Crit Care. 2020 Oct;59:32-34. doi: 10.1016/j.jcrc.2020.05.017. Epub 2020 May 29.
4
Assessment of Lupus Anticoagulant Positivity in Patients With Coronavirus Disease 2019 (COVID-19).2019年冠状病毒病（COVID-19）患者狼疮抗凝物阳性的评估
JAMA Netw Open. 2020 Aug 3;3(8):e2017539. doi: 10.1001/jamanetworkopen.2020.17539.
5
COVID-19 coagulopathy: an evolving story.新冠病毒感染相关凝血功能障碍：一个不断演变的故事。
Lancet Haematol. 2020 Jun;7(6):e425. doi: 10.1016/S2352-3026(20)30151-4.
6
Cautious interpretation of antiphospholipid antibodies in COVID-19.对新冠病毒肺炎中抗磷脂抗体的谨慎解读
Clin Chim Acta. 2020 Oct;509:166. doi: 10.1016/j.cca.2020.06.024. Epub 2020 Jun 15.
7
Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases.在 SARS-CoV-2 感染患者中出现抗磷脂抗体的频率和临床相关性：来自对 122 例病例进行的多中心研究的结果。
Clin Exp Rheumatol. 2020 Jul-Aug;38(4):754-759. Epub 2020 Jul 28.
8
Severe COVID-19 infection associated with endothelial activation.严重的2019冠状病毒病感染与内皮细胞激活有关。
Thromb Res. 2020 Jun;190:62. doi: 10.1016/j.thromres.2020.04.014. Epub 2020 Apr 15.
9
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.新型冠状病毒肺炎患者的凝血障碍与抗磷脂抗体
N Engl J Med. 2020 Apr 23;382(17):e38. doi: 10.1056/NEJMc2007575. Epub 2020 Apr 8.
10
Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)-Part I.2019冠状病毒病（COVID-19）中的止血维持与血栓形成预防——第一部分
Semin Thromb Hemost. 2020 Oct;46(7):757-762. doi: 10.1055/s-0040-1717139. Epub 2020 Oct 20.

引用本文的文献

1
COVID-19 coagulopathy and antiphospholipid syndrome.新型冠状病毒肺炎凝血病与抗磷脂综合征
Rev Colomb Reumatol. 2022 Jun;29:S25-S34. doi: 10.1016/j.rcreu.2021.02.013. Epub 2021 Aug 27.
2
The New Occurrence of Antiphospholipid Syndrome in Severe COVID-19 Cases with Pneumonia and Vascular Thrombosis Could Explain the Post-COVID Syndrome.在患有肺炎和血管血栓形成的重症 COVID-19 病例中抗磷脂综合征的新出现可能解释 COVID 后综合征。
Biomedicines. 2025 Feb 19;13(2):516. doi: 10.3390/biomedicines13020516.
3
Antiphospholipid Antibodies and COVID-19: A Systematic Review of Clinical Implications.

本文引用的文献

1
Coagulopathy of COVID-19 and antiphospholipid antibodies.新型冠状病毒肺炎的凝血功能障碍与抗磷脂抗体
J Thromb Haemost. 2020 Sep;18(9):E1-E2. doi: 10.1111/jth.14893. Epub 2020 May 28.
2
High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.严重严重急性呼吸综合征冠状病毒 2 型感染患者的血栓形成风险高：一项多中心前瞻性队列研究。
Intensive Care Med. 2020 Jun;46(6):1089-1098. doi: 10.1007/s00134-020-06062-x. Epub 2020 May 4.
3
Lupus anticoagulant is frequent in patients with Covid-19.狼疮抗凝物在新冠病毒肺炎患者中很常见。
抗磷脂抗体与新型冠状病毒肺炎：临床意义的系统评价
Immun Inflamm Dis. 2025 Feb;13(2):e70134. doi: 10.1002/iid3.70134.
4
Autoantibodies in COVID-19: implications for disease severity and clinical outcomes.新冠病毒病中的自身抗体：对疾病严重程度和临床结局的影响
Front Immunol. 2025 Jan 6;15:1509289. doi: 10.3389/fimmu.2024.1509289. eCollection 2024.
5
The well-defined antiphospholipid syndrome induced by COVID-19: a rare case report and review of the literature.由新型冠状病毒肺炎（COVID-19）引发的明确抗磷脂综合征：一例罕见病例报告及文献综述
Thromb J. 2024 Nov 8;22(1):99. doi: 10.1186/s12959-024-00669-6.
6
Autoantibodies to protein S may explain rare cases of coagulopathy following COVID-19 vaccination.针对 COVID-19 疫苗接种后发生罕见凝血功能障碍的患者，可检测蛋白 S 自身抗体。
Sci Rep. 2024 Oct 18;14(1):24512. doi: 10.1038/s41598-024-75514-x.
7
Is lupus anticoagulant testing with dilute Russell's viper venom clotting times reliable in the presence of inflammation?在存在炎症的情况下，采用稀释蝰蛇毒凝血时间进行狼疮抗凝物检测是否可靠？
Res Pract Thromb Haemost. 2024 Jul 26;8(6):102536. doi: 10.1016/j.rpth.2024.102536. eCollection 2024 Aug.
8
Effect of vitamin D on antiphospholipid antibodies in hospitalized patients with moderate to severe COVID-19.维生素 D 对中重度 COVID-19 住院患者抗磷脂抗体的影响。
Clinics (Sao Paulo). 2024 Aug 27;79:100474. doi: 10.1016/j.clinsp.2024.100474. eCollection 2024.
9
IgA Anti-β2-Glycoprotein I Antibodies as Markers of Thrombosis and Severity in COVID-19 Patients.IgA 抗β2-糖蛋白 I 抗体作为 COVID-19 患者血栓形成和严重程度的标志物。
Viruses. 2024 Jul 3;16(7):1071. doi: 10.3390/v16071071.
10
Antiphospholipid antibody-related hepatic vasculitis in a juvenile after non-severe COVID-19: a case report and literature review.抗磷脂抗体相关肝血管炎在非重症 COVID-19 后青少年中的发病：病例报告及文献复习。
Front Immunol. 2024 Apr 19;15:1354349. doi: 10.3389/fimmu.2024.1354349. eCollection 2024.
J Thromb Haemost. 2020 Aug;18(8):2064-2065. doi: 10.1111/jth.14867. Epub 2020 May 11.
4
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.新型冠状病毒肺炎患者的凝血障碍与抗磷脂抗体
N Engl J Med. 2020 Apr 23;382(17):e38. doi: 10.1056/NEJMc2007575. Epub 2020 Apr 8.
5
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.抗凝治疗与伴有凝血功能障碍的严重 2019 冠状病毒病患者的死亡率降低相关。
J Thromb Haemost. 2020 May;18(5):1094-1099. doi: 10.1111/jth.14817. Epub 2020 Apr 27.
6
The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false-positive results?普通肝素、依诺肝素和达那肝素对狼疮抗凝物检测的影响：活性炭能否消除假阳性结果？
Res Pract Thromb Haemost. 2019 Dec 10;4(1):161-168. doi: 10.1002/rth2.12264. eCollection 2020 Jan.
7
Clinical and laboratory practice for lupus anticoagulant testing: An International Society of Thrombosis and Haemostasis Scientific and Standardization Committee survey.狼疮抗凝物检测的临床和实验室实践：国际血栓与止血学会科学和标准化委员会调查。
J Thromb Haemost. 2019 Oct;17(10):1715-1732. doi: 10.1111/jth.14560. Epub 2019 Aug 1.
8
Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis.病毒感染后抗磷脂抗体产生的风险：一项系统评价和荟萃分析。
Lupus. 2018 Apr;27(4):572-583. doi: 10.1177/0961203317731532. Epub 2017 Sep 24.
9
Multifaceted effects of hydroxychloroquine in human disease.羟氯喹在人类疾病中的多方面作用。
Semin Arthritis Rheum. 2013 Oct;43(2):264-72. doi: 10.1016/j.semarthrit.2013.01.001. Epub 2013 Mar 5.
10
Lupus Anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results?炎症状态患者的狼疮抗凝物（LAC）检测：C反应蛋白会干扰LAC检测结果吗？
Thromb Res. 2010 Jan;125(1):102-4. doi: 10.1016/j.thromres.2009.09.001. Epub 2009 Sep 25.